|
시장보고서
상품코드
2008043
피부근염 시장 : 유형별, 치료 유형별, 유통 채널별, 지역별Dermatomyositis Market, By Type, By Treatment Type, By Distribution Channel, By Geography |
||||||
피부근염 시장은 2026년에 6억 3,770만 달러로 추정되고 있으며, 2033년까지 9억 3,160만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.5%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 6억 3,770만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 5.50% | 2033년 시장 규모 예측 : | 9억 3,160만 달러 |
피부근염은 근육에 염증을 일으키는 희귀한 질환입니다. 대칭적인 근위부 근력 저하, 피부 발진, 식도 기능 장애, 간질성 폐질환 등 피부 외의 증상도 나타납니다. 피부근염은 특히 성인에서 악성 종양과 밀접한 관련이 있습니다. 피부근염은 전신 질환으로 피부와 근육에 가장 흔하게 영향을 미치지만 관절, 식도, 폐, 드물게는 심장에도 영향을 미칠 수 있습니다. 피부근염은 특징적인 피부 소견과 대칭적인 근위부 골격근의 근력 저하를 보입니다. 또한 폐, 심혈관, 소화기 등 다른 장기 시스템에도 영향을 미칠 수 있습니다. 피부근염의 원인에는 유전적 요인, 면역학적 요인, 그리고 감염, 약물, 방사선 등의 환경적 요인 등 다양한 요인이 관여합니다.
또한 피부근육염에는 성인 피부근육염, 근염을 동반하지 않는 피부근육염, 청소년(소아) 피부근육염의 세 가지 유형이 있습니다. 근염을 동반하지 않는 피부근염은 피부 증상만 있고 관련 근육 증상이 없는 환자를 일컫는 용어입니다. 청소년(소아) 피부근염은 피부근염의 조기 발병형이며, 혈관 병변을 동반하는 전신성 자가면역성 염증성 근육 질환입니다. 근위부 대칭적 근력 저하, 특징적인 피부 병변 및 전신 증상이 특징입니다.
시장 역학
시장 진입 기업은 피부 근염에 대한 새로운 치료법을 개발하기 위해 노력하고 있으며, 이는 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2022년 5월, 임상 단계의 생명공학 기업 Kezar Life Sciences, Inc.는 피부근염(DM) 및 다발성근염(PM) 환자를 대상으로 한 제토밉소밉(KZR-616)의 PRESIDIO 임상 2상 시험 결과를 발표했습니다. PRESIDIO 시험 결과에 따르면 대부분의 DM 및 PM 환자에서 임상적으로 유의미한 종합 개선 점수(TIS)의 개선이 관찰되었습니다.
본 조사의 주요 특징.
- 이 보고서는 2025년을 기준연도로 하여 세계 피부근육염 시장, 시장 규모 및 예측 기간(2026-2033년)의 연평균 성장률(CAGR%)에 대해 상세히 분석하여 전해드립니다.
- 이 보고서는 다양한 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 시장 전략과 같은 매개 변수를 기반으로 세계의 피부 근염 시장의 주요 기업 개요을 프로파일링합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 피부근육염 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 범위
제3장 세계의 피부근염 시장에 관한 인사이트
제4장 세계의 피부근염 시장 : 유형별, 2026-2033년
제5장 세계의 피부근염 시장 : 치료 유형별, 2026-2033년
제6장 세계의 피부근염 시장 : 유통 채널별, 2026-2033년
제7장 세계의 피부근염 시장 : 지역별, 2026-2033년
제8장 기업 개요
제9장 섹션
KSADermatomyositis Market is estimated to be valued at USD 637.7 Mn in 2026 and is expected to reach USD 931.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 637.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.50% | 2033 Value Projection: | USD 931.6 Mn |
Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.
Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.
Market Dynamics
Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).
Key features of the study
- This report provides an in-depth analysis of the global dermatomyositis market, market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dermatomyositis market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Neovacs, Horizon Therapeutics plc., and Pfizer Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market
Dermatomyositis Market Segmentation
- By Type (Revenue, USD Mn, 2020 - 2033)
- Adult Dermatomyositis
- Dermatomyositis Sine Myositis
- Juvenile (Childhood) Dermatomyositis (JDMS)
- By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
- Anti-inflammatory Medication
- Immunosuppressive Drugs
- Immunoglobulin
- Others (Plasma Exchange, Monoclonal antibody among others)
- By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Octapharma AG
- Corbus Pharmaceuticals Holdings, Inc.
- CSL Limited
- Ermium Therapeutics
- Kezar Life Sciences Inc.
- Mallinckrodt Plc.
- Neovacs, Horizon Therapeutics plc.
- Pfizer Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Market Opportunity Map
3. Global Dermatomyositis Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Porter's Five Forces Analysis
- Key Developments
- Regulatory Scenario
- Reimbursement Scenario
- Merger & Acquisition Scenario
- Brand Mapping
4. Global Dermatomyositis Market, By Type, 2026 - 2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Adult Dermatomyositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Dermatomyositis Sine Myositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Juvenile (Childhood) Dermatomyositis (JDMS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
5. Global Dermatomyositis Market, By Treatment Type, 2026 - 2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Anti-inflammatory Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Immunosuppressive Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Others (Plasma Exchange, Monoclonal antibody among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
6. Global Dermatomyositis Market, By Distribution Channel, 2026 - 2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
7. Global Dermatomyositis Market, By Region, 2026 - 2033 (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Region at Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Company Profiles
- AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Corbus Pharmaceuticals Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ermium Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kezar Life Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mallinckrodt Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Neovacs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Horizon Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About us
